MARKET

CEMI

CEMI

Chembio
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.47
-1.05
-13.91%
Opening 15:42 12/04 EST
OPEN
6.03
PREV CLOSE
7.51
HIGH
6.63
LOW
5.90
VOLUME
6.27M
TURNOVER
--
52 WEEK HIGH
15.89
52 WEEK LOW
2.250
MARKET CAP
130.44M
P/E (TTM)
-5.3447
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
PD, CIIC, YEXT and CEMI among midday movers
Gainers: China HGS Real Estate (HGSH) +136%.Pioneer Power Solutions (PPSI) +54%.Star Peak Energy Transition (STPK) +45%.Fangdd Network Group (DUO) +41%.Sutro Biopharma (STRO) +35%.Collective Growth (CGROU) +34%.CIIG Merger (CIIC) +31%.AquaBounty Technologies (AQB) +30%.Collective
Seekingalpha · 2h ago
Mid-Morning Market Update: Markets Open Higher; Big Lots Earnings Top Expectations
Following the market opening Friday, the Dow traded up 0.48% to 30,114.19 while the NASDAQ rose 0.33% to 12,418.55. The S&P also rose, gaining 0.55% to 3,686.75.
Benzinga · 4h ago
Are Options Traders Betting on a Big Move in Chembio Diagnostics (CEMI) Stock?
Investors need to pay close attention to Chembio Diagnostics (CEMI) stock based on the movements in the options market lately.
Zacks · 6h ago
Li Auto, Ollie's Bargain Outlet Holdings leads premarket losers' pack
Francesca's Holdings (FRAN) -18% on filing for bankruptcy.Chembio Diagnostics (CEMI) -13% after FDA rejects Chembio's EUA application for rapid antibody test panel.Lizhi (LIZI) -12%.Ollie's Bargain Outlet Holdings (OLLI) -11% on Q3 earnings release.Cambium Networks (CMBM) -9% after prices secondary
Seekingalpha · 7h ago
Chembio slumps 13% on delay of U.S. nod for coronavirus antibody test
Chembio Diagnostics (CEMI) is down 13% premarket on increased volume in response to its disclosure that the FDA will not prioritize its application for emergency use authorization ((EUA)) of its DPP SARS-CoV-2
Seekingalpha · 7h ago
FDA to delay Chembio's EUA application for rapid antibody test panel
Chembio Diagnostics (CEMI) slips 11% in premarket, as the FDA has declined to review, on priority basis, the company's emergency use authorization ((EUA)) application for a rapid antibody test system, DPP SARS-CoV-2 IgM/IgG.The
Seekingalpha · 8h ago
FDA rejects Chembio' EUA application for rapid antibody test panel
Chembio Diagnostics (CEMI) slips 11% in premarket, as the FDA has declined to review the company's emergency use authorization ((EUA)) application for a rapid antibody test system, DPP SARS-CoV-2 IgM/IgG.The letter cited that
Seekingalpha · 8h ago
Comprehensive Diagnostics Remains a Priority As More Surges are Expected
, /PRNewswire/ -- When Pfizer and BioNTech SE announced earlier in November a request to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) of their mRNA vaccine candidate, BNT162b2 against SARS-CoV-2, it was unclear how soon the pharmaceuticals companies will get the green light to start distribution. The submission is based on a vaccine efficacy rate of 95%, and it seems the data has been convincing enough to be approved by the . Regulators in the U.K. granted emergency authorization to the vaccine developed by Pfizer and BioNTech, and the distribution of the first 800,000 doses is expected to start next week. The elderly and nursing home residents are to receive first priority, British Health Secretary said Wednesday, according to a report by the . U.K. Health Secretary said during a press conference that "I'm confident now, with the news today, that from spring, from Easter onward, things are going to be better. And we're going to have a summer next year that everyone can enjoy." Todos Medical Ltd. (OTC: TOMDF), BioNTech SE (NASDAQ: BNTX), Chembio Diagnostics, Inc. (NASDAQ: CEMI), Dynavax Technologies Corporation (NASDAQ: DVAX), Vaxart, Inc. (NASDAQ: VXRT)
PR Newswire - PRF · 1d ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CEMI. Analyze the recent business situations of Chembio through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CEMI stock price target is 9.00 with a high estimate of 10.00 and a low estimate of 8.00.
EPS
Institutional Holdings
Institutions: 113
Institutional Holdings: 8.14M
% Owned: 40.37%
Shares Outstanding: 20.18M
TypeInstitutionsShares
Increased
21
1.03M
New
26
-1.56M
Decreased
19
397.17K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+1.05%
Pharmaceuticals & Medical Research
+1.51%
Key Executives
Chairman/Executive Director
Gail Page
President/Chief Executive Officer/Director
Richard Eberly
Chief Financial Officer/Executive Vice President
Neil Goldman
Executive Vice President/Chief Technology Officer/Chief Scientific Officer
Javan Esfandiari
Vice President/Director of Sales/Director of Marketing
Chuck Caso
Independent Director
Katherine Davis
Independent Director
Mary Polan
Independent Director
John Potthoff
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About CEMI
Chembio Diagnostics, Inc. is a provider of point-of-care diagnostic products for the detection and diagnosis of infectious diseases. The Company is primarily focused on expanding its product portfolio based upon its Dual Path Platform (DPP). The Company's products include rapid tests for the detection of human immunodeficiency virus (HIV) 1/2 antibodies, and a multiplex rapid test for the detection of HIV and Syphilis antibodies. The Company’s point-of-care infectious disease portfolio is comprised of multiple commercial products and are performed with a tiny drop of blood from the fingertip and provide results in approximately 15 minutes. The Company’s products include DPP HIV 1/2, DPP HIV-Syphilis, DPP Syphilis Screen and Confirm, DPP Zika, DPP Leishmaniasis, STAT-PAK HIV 1/2, STAT-PAK Chagas, SURE CHECK HIV 1/2 and SURE CHECK HIV 1/2 Self- Test.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Chembio Diagnostics Inc stock information, including NASDAQ:CEMI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CEMI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CEMI stock methods without spending real money on the virtual paper trading platform.